Tremfya (guselkumab) is a Johnson & Johnson biologic approved for moderate to severe plaque psoriasis, active psoriatic arthritis, Crohn’s disease and ulcerative colitis. For skin and joint disease, FDA labeling puts adults on 100 mg at week 0, week 4, and every 8 weeks after that, so a maintenance year is about six to seven injections rather than twelve monthly fills.
That is the first thing to understand about any Tremfya price you see quoted. Nearly every published figure, including J&J’s own, is a five-figure per-dose number, and it only becomes comparable to other drugs once you spread it across the eight-week interval. Every figure below was verified on September 1 and 2, 2026. This page covers cost and paperwork only, not whether the drug is right for you.
What Does Tremfya Cost Without Insurance?
Johnson & Johnson publishes Tremfya’s list price on its own cost support pages, stated as of March 2025. Retail cash figures come from SingleCare’s live Tremfya pages, prices updated September 2, 2026. The Medicare row comes from CMS’s Medicare Part D Spending by Drug dataset, data year 2024, released June 25, 2026.
| Option | Low | Average / typical | High |
|---|---|---|---|
| Tremfya 100 mg pen, average retail cash | $13,879.25 | $13,879.25 | $13,879.25 |
| Tremfya 100 mg prefilled syringe, average retail cash | $13,391.26 | $13,391.26 | $13,391.26 |
| Tremfya, cash with a discount card (pen) | $13,876.25 | $13,876.25 | $13,876.25 |
| J&J published list price, one injection or infusion | $14,566.44 | $14,566.44 | $14,566.44 |
| Medicare Part D average per fill, 2024 | $13,428.78 | $13,428.78 | $13,428.78 |
| Crohn’s disease induction pack (two pens), list price | $29,132.88 | $29,132.88 | $29,132.88 |
| TREMFYA withMe Savings Program (commercial insurance only) | $0 | $0 | $0 |
| Johnson & Johnson Patient Assistance Program (income-qualified) | $0 | $0 | $0 |
The cross-source range for one uncovered 100 mg dose is roughly $13,391 to $14,566. Across the every-8-week maintenance schedule that is about $87,000 to $94,700 a year, or roughly $7,250 to $7,890 a month. The first year runs higher because the label adds a starting dose at week 4.
One caution on the discount-card row: SingleCare’s per-pharmacy figures move between sessions, so treat any named-chain quote as illustrative of the spread rather than as a fixed price. The average retail and as-low-as figures are the stable ones.
Note the vintage on the list price
J&J’s stated list price carries an as-of date of March 2025, which is roughly eighteen months old as of September 2026. That matters, because on most brand drugs the retail cash price sits well above list once pharmacy markup is added, and here it does not. SingleCare’s current average retail prices of $13,391.26 and $13,879.25 both sit below the $14,566.44 list figure, and CMS’s 2024 Part D average of $13,428.78 per fill does too.
The likeliest explanation is simply that the posted list figure has not been refreshed while the market moved. Treat $14,566.44 as the last confirmed manufacturer list price rather than as today’s number, and treat the $13,391 to $14,566 band as what a cash payer is actually quoted.
What Medicare’s own data shows
CMS Part D data is a useful cross-check because it reports what was paid nationally rather than what was advertised. In 2024, Part D covered 46,079 Tremfya fills for 10,848 beneficiaries at an average of $13,428.78 per fill and $618.8 million in total spending. Average spending per beneficiary was $57,041.35 for the year.
What Drives the Price
There is no biosimilar. FDA’s biosimilar product list, content current as of August 4, 2026, contains no guselkumab product. Without a licensed cheaper equivalent, there is nothing the pharmacy can substitute, which is why every route to a lower number on this page runs through a manufacturer program.
Which condition you are treating. Psoriasis and psoriatic arthritis run on 100 mg every 8 weeks. Crohn’s disease and ulcerative colitis start with an induction phase at weeks 0, 4 and 8, then move to 100 mg every 8 weeks starting at week 16 or 200 mg every 4 weeks starting at week 12. The 200 mg every-4-week option roughly doubles the number of doses in a year.
Whether the drug is infused or injected. J&J prices a single subcutaneous injection and a single IV infusion at the same $14,566.44, but an infusion adds a facility or infusion-suite charge that the drug price does not include. J&J’s own savings program has a separate component for administration costs precisely because of this.
Which device your prescription specifies. Tremfya comes as a pen, a One-Press patient-controlled injector and a prefilled syringe. SingleCare’s September 2026 data shows about $488 per dose between the syringe and the pen for the same 100 mg, which is roughly $3,200 a year.
Your insurance status, in both directions. The $0 savings card requires commercial or private insurance. The free-drug program is aimed at people who are uninsured or whose coverage does not fully meet their needs. Being commercially insured on a plan that excludes Tremfya puts you awkwardly between the two.
Cash Price vs. Insurance
For an uninsured patient, paying cash is not a realistic plan. Roughly $13,400 a dose, six or seven times a year, is not a bill people absorb, and unlike a generic there is no cheaper equivalent to fall back on. The route that matters is the Johnson & Johnson Patient Assistance Program, which J&J describes as available to patients who are uninsured or whose commercial, employer-sponsored or government coverage does not fully meet their needs, and which may supply the medicine at no cost for up to one year to those who meet the eligibility and income requirements.
If you have commercial insurance, run the claim and enroll in TREMFYA withMe. J&J advertises as little as $0 per dose for eligible commercially insured patients, split into Medicine Cost Support for the drug and Treatment Administration Cost Support for eligible lab tests and infusion administration. A maximum program benefit applies per calendar year, and unusually for a program this size, you can enroll without sharing income information.
There is a third program worth knowing by name. J&J’s Delay and Denial Support supplies Tremfya at no cost to eligible commercial patients when coverage is delayed more than five business days or denied outright, dispensed through a dedicated non-commercial pharmacy. Prior authorization fights on specialty biologics routinely run longer than five days, so ask about it the moment a claim stalls.
If a pharmacy or plan quotes you a figure that matches nothing on this page, our fair price checker is a quick way to test whether it is defensible.
How to Pay Less
-
Call TREMFYA withMe and ask about the Johnson & Johnson Patient Assistance Program by name. For an uninsured patient this is the only path that reliably ends at $0, and J&J states approved patients can receive the medicine at no cost for up to one year.
-
Enroll in the withMe savings card if you are commercially insured. Ask specifically about both halves of it, since the administration-cost piece covers eligible lab tests and infusion charges that the medicine card does not.
-
Ask about Delay and Denial Support the day a prior authorization stalls. Free drug while the appeal runs is worth more than any discount card, and eligibility turns on a five-business-day clock rather than on your income.
-
Do not waste time on a pharmacy discount card. The card is worth $3 on the pen. Our comparison of GoodRx vs. SingleCare explains where those cards genuinely help and where, as here, they do not.
-
Do not count on a copay foundation if you are uninsured. The HealthWell Foundation states that you must have some form of health insurance that covers part of your treatment, that drug discount cards do not qualify as insurance, and that it refers patients without prescription insurance to manufacturer programs instead. Most copay charities apply the same rule.
-
Price the surrounding care separately. A free or sliding-scale clinic can handle prescribing and monitoring visits, our guide to dermatologist costs without insurance covers the specialist visit, and if an infusion or specialty pharmacy bill has already arrived, our medical bill negotiation guide covers what to say before you pay it.
Bottom Line
Budget $13,391 to $14,566 per 100 mg dose of Tremfya if you are paying cash in September 2026, which is roughly $7,250 to $7,890 a month once you spread it across the every-8-week schedule, or about $87,000 to $94,700 a year in maintenance. Medicare Part D averaged $13,428.78 per fill in 2024, which lands squarely inside that band.
None of those are the numbers to plan around. With no biosimilar approved and discount cards worth $3, the whole question is which J&J program you qualify for: the withMe card if you are commercially insured, Delay and Denial Support if coverage is stalled, and the Patient Assistance Program if you are uninsured or underinsured. For the biologics priced the same way, see Skyrizi and Dupixent. For the oral options in the same treatment conversation, see Rinvoq, Otezla and, on the acne side of dermatology, Accutane and tretinoin. And if a hospital or infusion-center bill is the real problem, hospital charity care is the place to start.